C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Purchases Shares of 6,017 Kenvue Inc. (NYSE:KVUE)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, Holdings Channel.com reports. The fund purchased 6,017 shares of the company’s stock, valued at approximately $128,000.

Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. FMR LLC lifted its position in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. State Street Corp lifted its position in Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after acquiring an additional 399,846 shares during the last quarter. Finally, Harris Associates L P increased its stake in shares of Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after acquiring an additional 2,186,114 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 2.3 %

KVUE stock opened at $21.94 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock has a market capitalization of $42.07 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 2.16 and a beta of 1.45. The business’s fifty day moving average price is $21.33 and its two-hundred day moving average price is $22.02.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts anticipate that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KVUE shares. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Canaccord Genuity Group lowered their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.